Lumoxiti (Moxetumomab Pasudotox) is a CD22-directed cytotoxin. It is used to treat adults with hairy cell leukemia (HCL): that has come back or has not responded to last treatment, and have received minimum two other treatments, including a type of drug named purine nucleoside analog (PNA).
Dosage: The recommended lumoxiti dosage is 0.04 mg/kg administered as a 30 minute intravenous infusion on Days 1’st, 3’rd, & 5’th of each 28-day cycle. Continue moxetumomab pasudotox treatment for a maximum of six cycles, until the disease is progressive, or unacceptable toxicity occurs.
Side Effects: The most commonly reported lumoxiti side effects may include:
- Infusion related reactions
Warnings and Precautions:
Patients on moxetumomab pasudotox should be monitored for fluid balance and serum electrolytes to avoid fluid overload or electrolyte abnormalities.
Patients taking lumoxiti 1 mg injection are advised to maintain adequate hydration throughout treatment. Patients with the therapy of lumoxiti should be monitored for weight and blood pressure prior to each infusion during treatment.
Patients receiving lumoxiti dose must be monitored for renal function prior to each and every infusion throughout treatment. Nursing women with lumoxiti injection are advised to avoid breastfeeding while on receiving this medication.